Screener
Halozyme Therapeutics HALO Acquired in-process research and development expenses
Acquired in-process research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The source filing: Halozyme Therapeutics’s 10-K, filed February 17, 2026.
- Filed
- Feb 17, 2026, 4:08 PM EST
- Fiscal year
- FY2025
- Accession
- 0001159036-26-000024
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Research and development | 81,490 | 79,048 | 76,363 |
| Selling, general and administrative | 207,092 | 154,335 | 149,182 |
| Impairment of intangible asset | 48,700 | — | — |
| Acquired in-process research and development expense | 284,887 | — | — |
| Total operating expenses | 927,605 | 463,849 | 491,679 |
| Operating income | 469,006 | 551,475 | 337,574 |
| Other income (expense) | |||
| Investment and other income, net | 21,472 | 23,752 | 16,317 |
Item 16.Form 10-K Summary
FAQ
- What is Halozyme Therapeutics's acquired in-process research and development expenses?
- Halozyme Therapeutics (HALO) reported acquired in-process research and development expenses of $71.22M in Q4 2025.
- What does acquired in-process research and development expenses mean?
- This metric captures the costs associated with acquiring in-process research and development (IPR&D) projects from third parties. Unlike internal R&D, these costs are often one-time payments related to business combinations or licensing deals. It reflects the company's strategy of buying innovation rather than developing it entirely in-house.
Ask your AI about Halozyme Therapeutics's acquired in-process research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude